Beroni Group (NSX:BTG) (OTCMKTS:BNIGF) is an international biopharmaceutical enterprise dedicated to the innovation and commercialization of drugs and therapies to combat various global diseases such as cancer and infectious diseases. Its diversified portfolio is comprised of a US FDA approved virus diagnostic kit, an e-commerce platform for the sale of pharmaceutical products and a development pipeline targeting oncology and cell therapies. Beroni has operations in Australia, United States, China and Japan. To learn more about Beroni, please visit www.beronigroup.com.
Beroni Group Limited
NSX:BTG ISIN:AU000000BTG8
News
Beroni Group Limited (OTCMKTS:BNIGF) (NSX:BTG) advises that it has entered into an unsecured and interest free convertible loan agreement with a group of investors for a principal loan amount of US$410,397.
Beroni Group Limited (NSX:BTG) Beroni Enters Into Convertible Loan With Investor
Beroni Group Limited (OTCMKTS:BNIGF) (NSX:BTG) advises that it has entered into unsecured and interest free convertible loan agreements with two investors for an aggregate principal loan amount of US$291,545.
Beroni Group Limited (OTCMKTS:BNIGF) (NSX:BTG), an Australia-based biopharmaceutical enterprise, announced that its enhanced COVID-19 Antigen Rapid Test Kit - Colloidal Gold Method has been undergoing clinical trial in China, for eventual application to the National Medical Product Administration.
Beroni Group (OTCMKTS:BNIGF) (NSX:BTG) announced that it has received notification that its latest enhanced COVID-19 Antigen Rapid Test Kit has complied with the applicable essential requirements of the council directive 98/79/EEC in vitro diagnostics as amended.
Beroni Group (OTCMKTS:BNIGF) (NSX:BTG) is pleased to announce that it has signed a contract to build a new Research & Development centre in the Zhuhai National High-Tech Industrial Development Zone in China.
Beroni Group (OTCMKTS:BNIGF) (NSX:BTG) today announced that it has raised US$500K from the issue of convertible notes to an investor in China.
Beroni Group (OTCMKTS:BNIGF) (NSX:BTG) announced that it has received part payment of a US$1.07M (JPY117.5M) order for its SARS-CoV-2 Antigen Test Kit from a Japanese pharmaceutical company based in Tokyo.
Beroni Group Limited (OTCMKTS:BNIGF) (NSX:BTG), an Australia-based biopharmaceutical enterprise, today announced that its article has been accepted for publication and undergone full review in the FEBS Journal.
Beroni Group (OTCMKTS:BNIGF) (NSX:BTG), an Australia-based biopharmaceutical enterprise, today announced that PENAO Pty Ltd has been approved by the Australian government for the annual 43.5% R&D rebate of eligible expenditure.
16,778 COMPANY PROFILE VIEWS
- This Page Viewed: (Last 7 Days: 41) (Last 30 Days: 217) (Since Published: 16778)